10-Q: Allurion Restructures Amid Revenue Slump, Going Concern

Allurion Technologies reports a significant revenue decline and increased net loss, leading to a major restructuring and raising substantial doubt about its ability to continue as a going concern.

Summary

• Allurion Technologies, Inc. filed a Form 10-Q for the quarter ended June 30, 2025, which includes a restatement of previously issued unaudited financial statements for Q2 2024 and Q1 2025, and audited statements for fiscal years 2023 and 2024.
• The restatement was due to an error in historical consolidated financial statements related to overstatements and understatements of Other comprehensive income (loss) and Other income (expense), stemming from a material weakness in internal controls related to insufficient public company and technical accounting experience.
• The error had no impact on revenue, gross profit, operating expenses, operating profit (loss), or cash and cash equivalents.
• The company reported a net loss of $10.836 million for the six months ended June 30, 2025, compared to a net loss of $6.326 million for the same period in 2024.
• Revenue decreased by 58% to $8.959 million for the six months ended June 30, 2025, from $21.152 million in the prior year, primarily due to distributor transitions, reduced sales and marketing investment, and a temporary sales suspension in France.
• Allurion announced a strategic restructuring plan on August 5, 2025, focusing on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry.
• The restructuring includes a reduction in force of approximately 70 employees, or 65% of its workforce, expected to be substantially completed by the end of Q3 2025, incurring an estimated $1.5 million in severance costs.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date due to recurring losses, anticipated negative operating cash flows, and potential non-compliance with credit facility covenants.
• The AUDACITY pivotal trial for the Allurion Balloon met its responder rate co-primary endpoint, with 58% of subjects losing over 5% total body weight at 48 weeks (p=0.0089).
• The rate of serious adverse events (SAE) in the AUDACITY trial was 3.1%, noted as the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon.
• The fourth and final module of the premarket approval application (PMA) for the Allurion Balloon was submitted to the FDA on July 7, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a significant revenue decline, increased net losses, and an accumulated deficit. The 'going concern' warning, coupled with material weaknesses in internal controls and a large workforce reduction, indicates substantial operational and financial challenges, despite some positive clinical trial results and strategic shifts.

Positives

• The AUDACITY pivotal trial met its responder rate co-primary endpoint, with 58% of Allurion Balloon subjects losing more than 5% of their total body weight at 48 weeks (p-value = 0.0089).
• The serious adverse event rate in the AUDACITY trial was 3.1%, which is the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for weight loss.
• Sales of the Allurion Balloon in France resumed on February 12, 2025, after the French regulatory authority (ANSM) repealed its temporary suspension.
• Net cash used in operating activities slightly improved, decreasing to $17.082 million for the six months ended June 30, 2025, from $17.563 million in the same period of 2024.
• Loss from operations improved to $14.234 million for the six months ended June 30, 2025, from $20.736 million in the same period of 2024.

Negatives

• Revenue decreased significantly by 58% to $8.959 million for the six months ended June 30, 2025, compared to $21.152 million for the same period in 2024.
• Gross profit decreased by 58% to $6.658 million for the six months ended June 30, 2025, from $15.859 million in the prior year.
• Net loss increased to $10.836 million for the six months ended June 30, 2025, compared to $6.326 million for the same period in 2024.
• The company has incurred recurring losses since inception and expects to continue generating operating losses for the foreseeable future.
• As of June 30, 2025, the accumulated deficit reached $233.0 million.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year.
• Material weaknesses in internal control over financial reporting were identified, including insufficient segregation of duties, lack of sufficient staff with public company and technical accounting experience, and insufficient information systems controls.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025.
• A strategic restructuring plan includes a reduction in force of approximately 70 employees, or 65% of the workforce, indicating significant operational challenges.
• The AUDACITY trial's comparative co-primary endpoint for weight loss at 48 weeks (3.77% mean difference) was less than the pre-specified 3% superiority margin (p-value=0.1616), though additional analyses using imputation methods met the margin.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows.
• Existing material weaknesses in internal control over financial reporting, which led to financial statement restatements and could impact future financial reporting reliability.
• The strategic restructuring and reduction in force may not result in anticipated savings, could incur higher-than-expected costs, and may disrupt business operations, including retention of remaining employees.
• Limited resources and workforce reduction may negatively impact R&D and clinical trial activities or expose the company to cybersecurity risks.
• Litigation risk from Vanderbilt University Medical Center seeking approximately $2.5 million for alleged breach of a Clinical Trial Agreement.
• Exposure to foreign currency exchange rate fluctuations, which could materially impact revenues and expenses.
• Dependence on gaining broader market acceptance of current products and expanding the customer base in existing or new target markets.
• Challenges in obtaining and maintaining timely regulatory approvals for existing and new products in various markets, including the U.S. FDA.
• Fluctuations in financial results due to timing of orders, foreign currency exchange rates, available selling days, product mix, and geographic mix.
• Potential adverse effects from substantial changes to U.S. federal fiscal, tax, and other policies, such as those from the One Big Beautiful Bill Act (OBBBA).

Future Outlook

The company intends to focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry. It has signed a term sheet with a strategic partner to expand ex-US distribution and potentially co-develop a novel GLP-1 drug-eluting intragastric balloon. A protocol for a prospective, multi-center study on the combination of the Allurion Program with low-dose GLP-1 has been submitted to IRBs in Europe, with enrollment expected to begin this year. The company is transitioning to distribution partners with access to GLP-1 prescribing physician networks. The fourth and final module of the PMA application for U.S. FDA approval was submitted on July 7, 2025, with marketing authorization targeted no later than June 30, 2026. The company expects to continue incurring net losses for the foreseeable future and will require additional funding through equity or debt financings.

Management Comments

• Management believes the Allurion Program is synergistic in combination with other weight loss therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists.
• Management expects to continue to incur net losses for the foreseeable future as we focus on obtaining regulatory approvals for our products in new markets, refining our sales and marketing strategies, and continuing research and development efforts to further enhance our existing products.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for a period of one year from the date that these condensed consolidated financial statements are issued.

Industry Context

The company's strategic shift towards low-dose GLP-1 combination therapy and muscle mass maintenance, along with transitioning to distribution partners with GLP-1 prescribing networks, indicates a direct response to the growing prominence of GLP-1 receptor agonists in the weight loss market. This move positions the Allurion Program as a complementary solution rather than a standalone alternative, aiming to leverage the increasing adoption of GLP-1s and address concerns about muscle wasting associated with some weight loss interventions.

Comparison to Industry Standards

• The rate of serious adverse events (SAE) in Allurion Balloon subjects in the AUDACITY trial was 3.1%, which is explicitly stated as the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for weight loss.

Management Changes

Corporate Governance

Legal Proceedings

• Vanderbilt University Medical Center filed a complaint on August 12, 2025, against the company in the United States District Court for the Middle District of Tennessee, alleging breach of a Clinical Trial Agreement and seeking approximately $2.5 million in damages for failing to reimburse medical expenses incurred in treating a patient.

Related Party Transactions

• RTW Investments, L.P. (a significant shareholder with director designation rights) is involved in multiple financing agreements, including the Amended Note Purchase Agreement for $48.0 million in convertible notes, participation in the July 2024 Public Offering ($0.3 million), the July 2024 Private Placement ($2.7 million), the New RIFA (additional $7.5 million revenue interest financing), and the January 2025 Private Placement ($2.5 million).
• The Second Amendment to Note Purchase Agreement with RTW included a mandatory conversion of $5.0 million of RTW Convertible Notes into common stock.
• A lease agreement for office space in Paris, France, with LNMP JPBC Invest (a related party through former company officers) was terminated in February 2024.

Stakeholder Impact

• Shareholders face significant dilution from multiple recent equity offerings and warrant exercises, as well as potential future dilution from convertible notes and the Chardan Equity Facility.
• Shareholders are exposed to substantial risk due to the company's 'going concern' warning, recurring losses, and declining revenue, which could negatively impact share price and investment value.
• Employees are significantly impacted by the strategic restructuring plan, which includes a reduction in force of approximately 65% of the workforce, leading to job losses and potential morale issues for remaining staff.
• Customers and distributors may experience changes due to the company's initiated distributor transitions and a shift in sales and marketing strategy from business-to-business to customer and away from direct-to-customer.
• Creditors, particularly RTW Investments, L.P., have significant financial exposure through convertible notes and revenue interest financing agreements, with specific covenants tied to the company's financial performance and regulatory milestones.

Next Steps

• Substantially complete the reduction in force of approximately 70 employees by the end of the third quarter of 2025.
• Begin enrollment for a prospective, multi-center study on the combination of the Allurion Program with a low-dose of GLP-1 for weight loss and muscle mass maintenance.
• Continue efforts to obtain marketing authorization from the U.S. Food & Drug Administration (FDA) for the commercialization of the Product in the United States no later than June 30, 2026.
• Implement and maintain effective internal controls over financial reporting to remediate existing material weaknesses, including hiring additional accounting staff, implementing a new ERP system, and establishing additional review controls.

Key Dates

Recommendation

The company is in a precarious financial position, explicitly stating 'substantial doubt about its ability to continue as a going concern.' This is compounded by a drastic 58% revenue decline, persistent net losses, and identified material weaknesses in internal controls. While the AUDACITY trial showed some positive clinical outcomes and the French market re-opened, these are overshadowed by the severe financial distress, a massive 65% workforce reduction, and ongoing litigation. The continuous need for capital raises, often at significantly lower prices, indicates severe liquidity challenges and substantial dilution risk for existing shareholders. A seasoned investor would view these factors as highly indicative of a company facing existential threats, warranting an immediate exit.

Keywords

Allurion, weight loss, medical device, intragastric balloon, SEC filing, 10-Q, financial results, restructuring, going concern, FDA approval, GLP-1, clinical trial, corporate governance, stock market, investment